SEC I	Form 4
-------	--------

FORM	4
------	---

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

			013		ivestment Con	Ipany Act of 1940				
1. Name and Address of Reporting Person* Bozigian Haig P.				uer Name <b>and</b> Ticke <u>UROCRINE E</u>	υ.	<sup>/mbol</sup> I <u>CES INC</u> [ NBIX		tionship of Reporting Person(s) to Issuer (all applicable) Director 10% Owner Officer (give title Other (specify below) below)		
(Last) (First) (Middle) NEUROCRINE BIOSCIENCES, INC. 12780 EL CAMINO REAL				te of Earliest Transa 1/2010					lent, Developm	
(Street) SAN DIEGO	CA	92130	4. If A	mendment, Date of	Original Filed	Month/Day/Year)	6. Indiv Line) X	,	p Filing (Check A ne Reporting Pers ore than One Rep	on
(City)	(State)	(Zip)						1 010011		
		Table I - No	on-Derivative	Securities Acq	uired, Dis	oosed of, or Benefi	cially (	Dwned		
1 Title of Security	(Instr 3)		2. Transaction	2A. Deemed	3.	4. Securities Acquired (A)	or	5. Amount of	6. Ownership	7. Nature of

Title of Security (Instr. 3)	Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (	ction	4. Securities A Disposed Of (I			Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) of (D) (Instr. 3, 4 and 5)		ate	7. Title and of Securiti Underlyin Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option <sup>(1)</sup>	\$2.59	05/11/2010		A		150,000		06/11/2010	05/11/2017	Common Stock	150,000	\$0	150,000	D	

Explanation of Responses:

1. Represents option of which 1/36th of the shares underlying the option becomes vested and exercisable on June 11, 2010, an additional 1/36th of the shares underlying the option becomes vested and exercisable each month thereafter.

Remarks:

## <u>Margaret E. Valeur-Jensen, By</u> Power of Attorney

05/12/2010

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.